Altimmune (ALT) EPS (Weighted Average and Diluted) (2014 - 2026)
Altimmune (ALT) reported EPS (Weighted Average and Diluted) of -$0.18 for Q1 2026, up 30.77% year-over-year from -$0.14 in Q1 2025, and up 30.77% quarter-over-quarter from -$0.26 in Q4 2025.
Altimmune (ALT) EPS (Weighted Average and Diluted) (2014 - 2026) Analysis & Trends
Altimmune (ALT) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.18 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.18, up 30.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.92 (up 26.98% YoY), and the FY2025 annual result was -$1.0, up 25.37% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$0.18 in Q1 2026 per ALT's latest filing, from -$0.26 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.18 in Q1 2026 and troughed at -$0.56 in Q4 2023.
- A 5-year average of -$0.35 and a median of -$0.34 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) declined 27.27% in 2023, then jumped 41.07% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.44 in 2022, then decreased by 27.27% to -$0.56 in 2023, then surged by 41.07% to -$0.33 in 2024, then increased by 21.21% to -$0.26 in 2025, then surged by 30.77% to -$0.18 in 2026.
- Business Quant data shows ALT's EPS (Weighted Average and Diluted) at -$0.18 in Q1 2026, -$0.26 in Q4 2025, and -$0.21 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.26 |
| Sep 30, 2025 | -0.21 |
| Jun 30, 2025 | -0.27 |
| Mar 31, 2025 | -0.26 |
| Dec 31, 2024 | -0.33 |
| Sep 30, 2024 | -0.32 |
| Jun 30, 2024 | -0.35 |
| Mar 31, 2024 | -0.34 |
| Dec 31, 2023 | -0.56 |
| Sep 30, 2023 | -0.39 |
| Jun 30, 2023 | -0.32 |
| Mar 31, 2023 | -0.40 |
| Dec 31, 2022 | -0.44 |
| Sep 30, 2022 | -0.48 |
| Jun 30, 2022 | -0.42 |
| Mar 31, 2022 | -0.44 |
| Dec 31, 2021 | -0.56 |
| Sep 30, 2021 | -0.81 |
| Jun 30, 2021 | -0.60 |